Last April Dr Timothy Messitt from EpiVax delivered a presentation about the next wave of vaccine design on immune-derived vaccines at the World Vaccine Congress Washington.
See below the key highlights of his presentation:
Immunome-derived are T cell epitope driven vaccines that were developed in order to improve safety (limited potential for autoimmunity) and immunogenicity. Would like to take this into biodefense portfolio.
The focus is on T cell epitopes being able to predict T cell epitopes (Class 1 and 2 MHC binding) using EpiMatrix. The process goes through the following phases:
1. T cell epitope identification:
■CLUSTIMERS (identifies epitope clusters); potent epitops are promiscuous
■CONSERVATRIX finds conserved 9mers to be able to protect against as many strains possible
■Removal of cross-reactive epitopes
2. Expressing epitopes, usually by DNA plasmids followed with peptide boost; optimized whole proteins or VLPs with iso-optimized proteins
3. In vivo evaluation by HLA binding assays
Current vaccines: Burk/Tuly/MP, HIV/TB, Smallpox (VennVax) and others
The company is focusing on an accelerated vaccine approach focusing on biodefense and is planning to integrate all technologies in a web-based toolkit, iVax (currently beta testing it).
Dr Timothy Messitt, Manager, Business Development, EpiVax
Visit our Website: http://www.terrapinn.com/2013/world-vaccine-congress-washington/index.stm
Read our blog: http://blogs.terrapinn.com/vaccinenation/
Follow us on Twitter: @vaccinenation
Join our Linkedin group: http://www.linkedin.com/groups/Vaccine-Nation-1351197